ECSP014068A - PROCEDURE TO REGULATE ANGIOGENESIS USING RYK PROTEIN - Google Patents
PROCEDURE TO REGULATE ANGIOGENESIS USING RYK PROTEINInfo
- Publication number
- ECSP014068A ECSP014068A EC2001004068A ECSP014068A ECSP014068A EC SP014068 A ECSP014068 A EC SP014068A EC 2001004068 A EC2001004068 A EC 2001004068A EC SP014068 A ECSP014068 A EC SP014068A EC SP014068 A ECSP014068 A EC SP014068A
- Authority
- EC
- Ecuador
- Prior art keywords
- ryk
- angiogenesis
- diseases
- procedure
- proteins
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000006884 regulation of angiogenesis Effects 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se encontró que la proteína Ryk tenia una novedosa actividad en la regulación de la angiogenesis, se construyeron nuevas proteínas Ryk variantes que son ventajosas para modular la actividad formadora de capilares de las células endoteliales, las proteínas Ryk variantes pueden ser utilizadas como agentes terapéuticos en enfermedades tales como el cáncer, la cicratización de heridas, las retinopatías diabéticas, la degeneración macular y las enfermedades cardiovasculares, así como otras enfermedades o trastornos clínicos en la que la angiogenesis esta involucrada en la causa o el tratamiento de la enfermedad.It was found that the Ryk protein had a novel activity in the regulation of angiogenesis, new variants Ryk proteins were constructed that are advantageous to modulate the capillary-forming activity of endothelial cells, the Ryk variants proteins can be used as therapeutic agents in diseases such as cancer, wound cyclization, diabetic retinopathies, macular degeneration and cardiovascular diseases, as well as other diseases or clinical disorders in which angiogenesis is involved in the cause or treatment of the disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56878300A | 2000-05-10 | 2000-05-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP014068A true ECSP014068A (en) | 2002-02-25 |
Family
ID=24272718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2001004068A ECSP014068A (en) | 2000-05-10 | 2001-05-09 | PROCEDURE TO REGULATE ANGIOGENESIS USING RYK PROTEIN |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1287121A2 (en) |
| JP (1) | JP2004527206A (en) |
| AR (1) | AR028424A1 (en) |
| AU (1) | AU2001261343A1 (en) |
| CA (1) | CA2408349A1 (en) |
| CO (1) | CO5300464A1 (en) |
| DO (1) | DOP2001000164A (en) |
| EC (1) | ECSP014068A (en) |
| GT (1) | GT200100079A (en) |
| PE (1) | PE20011218A1 (en) |
| SV (1) | SV2002000442A (en) |
| UY (1) | UY26696A1 (en) |
| WO (1) | WO2001085789A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501523B2 (en) | 2014-07-18 | 2019-12-10 | Sanofi | IL-8 level based method of predicting the outcome of colon cancer treatment |
| US11033606B2 (en) | 2011-04-26 | 2021-06-15 | Sanofi | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050180959A1 (en) * | 2002-02-06 | 2005-08-18 | Karsten Eulenberg | Kinases involved in the regulation of energy homeostasis |
| JP2024535691A (en) * | 2021-08-18 | 2024-10-02 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Anti-receptor tyrosine kinase-related protein (Ryk) antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07506969A (en) * | 1992-05-11 | 1995-08-03 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | Molecules similar to receptor tyrosine kinases |
| WO1996020403A1 (en) * | 1994-12-23 | 1996-07-04 | Ludwig Institute For Cancer Research | Assay, receptor proteins and ligands |
| EP1084245B1 (en) * | 1998-06-11 | 2006-03-29 | AstraZeneca AB | Human receptor tyrosine kinase |
| WO2000024415A2 (en) * | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
-
2001
- 2001-05-07 AR ARP010102149A patent/AR028424A1/en not_active Application Discontinuation
- 2001-05-07 GT GT200100079A patent/GT200100079A/en unknown
- 2001-05-08 UY UY26696A patent/UY26696A1/en not_active Application Discontinuation
- 2001-05-09 EP EP01935233A patent/EP1287121A2/en not_active Withdrawn
- 2001-05-09 EC EC2001004068A patent/ECSP014068A/en unknown
- 2001-05-09 CA CA002408349A patent/CA2408349A1/en not_active Abandoned
- 2001-05-09 CO CO01036462A patent/CO5300464A1/en unknown
- 2001-05-09 AU AU2001261343A patent/AU2001261343A1/en not_active Abandoned
- 2001-05-09 SV SV2001000442A patent/SV2002000442A/en not_active Application Discontinuation
- 2001-05-09 WO PCT/US2001/015043 patent/WO2001085789A2/en not_active Ceased
- 2001-05-09 JP JP2001582388A patent/JP2004527206A/en active Pending
- 2001-05-10 DO DO2001000164A patent/DOP2001000164A/en unknown
- 2001-05-10 PE PE2001000417A patent/PE20011218A1/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033606B2 (en) | 2011-04-26 | 2021-06-15 | Sanofi | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) |
| US10501523B2 (en) | 2014-07-18 | 2019-12-10 | Sanofi | IL-8 level based method of predicting the outcome of colon cancer treatment |
| US11208461B2 (en) | 2014-07-18 | 2021-12-28 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CO5300464A1 (en) | 2003-07-31 |
| UY26696A1 (en) | 2001-12-28 |
| EP1287121A2 (en) | 2003-03-05 |
| SV2002000442A (en) | 2002-07-03 |
| DOP2001000164A (en) | 2002-05-15 |
| JP2004527206A (en) | 2004-09-09 |
| PE20011218A1 (en) | 2002-02-01 |
| GT200100079A (en) | 2001-12-31 |
| CA2408349A1 (en) | 2001-11-15 |
| AR028424A1 (en) | 2003-05-07 |
| AU2001261343A1 (en) | 2001-11-20 |
| WO2001085789A2 (en) | 2001-11-15 |
| WO2001085789A3 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28396A1 (en) | VEGF TRUMPS AND THERAPEUTIC USES OF THE SAME | |
| DK1641483T3 (en) | Fusion Proteins | |
| ATE290401T1 (en) | TOPICAL AGENTS FOR NAIL FUNGUS DISEASES | |
| CY1119951T1 (en) | COMPOSITIONS FOR INCREASING TELOMERASING ACTIVITY AND TREATMENT OF HIV INFECTION | |
| IL117645A (en) | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration | |
| TR200101307T2 (en) | Antranilic acid amides and their use as drugs. | |
| CY1108932T1 (en) | Compounds 4- (heterocyclyl) -benzenesulfoximine for the therapeutic treatment of inflammatory diseases | |
| EA200400482A1 (en) | KERATINOCYCES SUITABLE FOR APPLICATION AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF THE RAS | |
| DE59811158D1 (en) | USE OF ERYTHROPOIETIN AND IRON PREPARATIONS FOR THE PRODUCTION OF PHARMACEUTICAL COMBINATION PREPARATIONS FOR THE TREATMENT OF RHEUMATIC DISEASES | |
| ES2180629T3 (en) | THERAPEUTIC USES OF BACTERICIDE PROTEIN / PERMEABILITY INCREASED PROTEIN PRODUCTS. | |
| AR046993A1 (en) | QUINAZOLINE DERIVATIVES | |
| AR012193A1 (en) | NEW THERAPEUTIC COMBINATIONS | |
| ATE462424T1 (en) | THERAPEUTIC USE OF NEBULATED S-NITROSOGLUTATHIONE IN CYSTIC FIBROSIS | |
| MXPA04005204A (en) | Hydrazonopyrazole derivatives and their use as therapeutics. | |
| ATE311191T1 (en) | APOPTOTIC BODY FOR USE IN THE TREATMENT OF T-CELL-MEDIATED AND INFLAMMATORY DISEASES | |
| PT1343472E (en) | TIXOTROPIC NASAL SPRAY | |
| DOP2001000164A (en) | METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN | |
| ATE556134T1 (en) | MESENCHYMA STEM CELLS AND USES THEREOF | |
| EE200100188A (en) | Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| MX2024014811A (en) | Pegylated menaquinol compositions and methods of treatment | |
| DE602005020178D1 (en) | 5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS | |
| DE60107444D1 (en) | USE OF A POLLEN EXTRACT CONTAINER FOR THE TREATMENT OF EDEMS | |
| ES2134254T3 (en) | EXPRESSION OF THE OP-1 OSTEOGENIC FACTOR OF SPODOPTERA FRUGIPERDA CELLS INFECTED WITH RECOMBINANT BACULOVIRUSES. | |
| DOP2001000141A (en) | PROTEIN ACTING AS AN ANGIOGENIC MODULATOR | |
| IT1320192B1 (en) | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PSORIASIS. |